This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, randomized, single-blinded trial of two Hepatitis B immunization regimens in 150 HIV-negative, Hepatitis B core antibody, Hepatitis B surface antigen, and surface antibody negative youth. The randomization will be restricted, so that the percentage of either gender does not exceed 60% of the subjects on either of the two arms. Vaccinations will be given in a two-dose refimen at 0 and six months and the primary outcome will be seroresponsiveness one month after the six-month dose. Safety and tolerability will also be assessed.
Showing the most recent 10 out of 203 publications